• Novo Nordisk's EVOKE trials show no statistically significant reduction in Alzheimer's progression
  • Shares plummet 8.4% for Novo Nordisk and 5.2% for Eli Lilly as GLP-1 dementia hopes dim
  • Extension phase of trials to be discontinued due to lack of efficacy

Novo Nordisk's highly anticipated EVOKE and EVOKE+ phase 3 trials testing oral semaglutide in early-stage Alzheimer's disease have failed to demonstrate a statistically significant reduction in disease progression, sending shockwaves through the pharmaceutical sector and triggering sharp declines in related stocks.

The Danish pharmaceutical giant saw its shares tumble 8.4% in Copenhagen trading Thursday, while Eli Lilly shares dropped 5.2% in New York as investors rapidly reassessed the prospects for GLP-1 drugs in dementia treatment. The selloff reflected broader concerns about the repurposing potential of metabolic drugs for neurological conditions.

According to people familiar with the matter, the two large, double-blind global trials enrolled over 3,800 adults with early symptomatic Alzheimer's disease, specifically those with mild cognitive impairment or mild dementia who were amyloid-positive. While semaglutide showed improvement in some Alzheimer's-related biomarkers, this did not translate to meaningful clinical benefit in slowing disease progression as measured by the Clinical Dementia Rating – Sum of Boxes (CDR-SB) assessment.

"The data simply didn't support continuing down this path," said one source close to the trials, who requested anonymity because the results haven't been formally presented. "When you're dealing with Alzheimer's, the clinical endpoints are what matter, and semaglutide didn't move the needle where it counts for patients."

The company confirmed that the one-year extension phase of both trials will be discontinued due to lack of efficacy. Full results are expected to be presented at upcoming major neurology conferences, where they will face intense scrutiny from researchers and clinicians.

Novo Nordisk declined to comment beyond its official statement, though company representatives emphasized that semaglutide's established position in diabetes and obesity treatment remains unaffected by the Alzheimer's trial results. Efforts to reach Eli Lilly executives for comment on the read-across implications for their own dementia programs were unsuccessful.

The failure represents a significant setback for Alzheimer's research, coming at a time when the pharmaceutical industry had been increasingly optimistic about repurposing GLP-1 receptor agonists for neurological conditions. The class of drugs had shown promise in observational studies and smaller trials, fueling speculation that they might offer a new approach to treating dementia.

Trading desks reported heavy volume in pharmaceutical stocks throughout the session, with particular pressure on companies developing similar dementia programs. The negative results reinforce the challenging history of Alzheimer's drug development, which has been marked by repeated setbacks despite massive research investments.

Analysts noted that while the outcome is disappointing for the Alzheimer's community, it doesn't fundamentally alter Novo Nordisk's strong position in metabolic diseases. The company's GLP-1 drugs continue to dominate the diabetes and obesity markets, with over 37 million patient-years of semaglutide exposure across indications.

Correction: An earlier version of this article misstated the number of patients enrolled in the trials. The correct figure is over 3,800 adults.